Approved indications: Anagrelide is FDA‑approved to treat thrombocythemia (very high platelet counts) caused by myeloproliferative neoplasms such as essential thrombocythemia, polycythemia vera, and related bone marrow diseases, to lower platelets, reduce blood clot risk, and improve clotting or bleeding symptoms.

Off‑label uses (evidence mainly from small studies and clinical experience):

• Second‑line cytoreductive treatment in essential thrombocythemia when standard first‑line drugs such as hydroxyurea are not tolerated or do not control platelets adequately.
• Control of high platelet counts in other myeloproliferative neoplasms when alternative agents are unsuitable or contraindicated.

Efficacy expectations:

• Platelet counts usually start to fall within about 1–2 weeks after starting therapy, with full response (platelets below about 600,000/µL) often reached within 4–12 weeks once the dose is properly adjusted.
• When effective, most patients maintain safer platelet levels long term and experience fewer thrombotic (clotting) and thrombo‑hemorrhagic complications, but treatment generally needs to continue indefinitely.
• Compared with hydroxyurea, anagrelide lowers platelet counts just as well but may be slightly less effective at preventing some arterial clots and may cause more heart‑related side effects, so many clinicians reserve it for patients who cannot use hydroxyurea or, in some centers, for selected younger patients.

Typical dosing and how to take it:

• Adults: the usual starting dose is 0.5 mg four times daily or 1 mg twice daily by mouth; most people respond on a total daily dose of about 1.5–3 mg, divided into two to four doses.
• Children 7 years and older: a common starting dose is 0.5 mg once daily, then gradually increased based on platelet counts and tolerance.
• Take anagrelide at the same times each day, with or without food; taking it with food or spreading doses out may lessen stomach upset and palpitations.
• Swallow the capsules whole with water and do not crush, open, or chew them.

Special dosing instructions:

• Doses are adjusted slowly, usually by no more than 0.5 mg per day in any one week, to bring the platelet count below about 600,000/µL and ideally into or near the normal range.
• Do not take more than 2.5 mg at one time or more than 10 mg total in one day.
• In moderate liver impairment, treatment is typically started at 0.5 mg once daily with careful monitoring, and the drug is generally avoided in severe liver disease.
• Treatment is often long term; stopping suddenly can cause platelets to rebound to very high levels within days, so any dose changes or discontinuation should be guided by your clinician.

Missed dose and overdose:

• If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; if it is close to the next dose, skip the missed one and resume your regular schedule—do not double the next dose.
• In case of overdose, serious low platelets, bleeding, very fast heartbeat, or low blood pressure may occur; stop the medicine and seek emergency care or call poison control so clinicians can monitor platelet counts, heart rhythm, blood pressure, and signs of bleeding and provide supportive treatment.

Common side effects (often mild to moderate, especially in the first weeks):

• Headache, dizziness, fatigue, and a general feeling of weakness.
• Fast or pounding heartbeat, palpitations, ankle or leg swelling, and fluid retention.
• Diarrhea, nausea, abdominal pain, gas, loss of appetite, indigestion, and vomiting.
• Shortness of breath, cough, skin rash or itching, back pain, and fever.

Serious or rare adverse effects needing immediate medical attention:

• Chest pain or pressure, severe shortness of breath, fainting, or very fast or irregular heartbeat, which may signal serious heart rhythm problems or heart failure.
• Signs of severe bleeding, including black or bloody stools, vomiting blood or material that looks like coffee grounds, coughing up blood, or unusual bruising or bleeding that will not stop.
• New or worsening breathing problems, persistent cough, fever, or chest discomfort that could indicate pulmonary hypertension or lung inflammation (interstitial lung disease).
• Severe allergic reactions such as hives, trouble breathing, or swelling of the face, lips, tongue, or throat.
• Possible liver or kidney injury, suggested by yellowing of the skin or eyes, dark urine, very little urine, or severe abdominal pain.

Warnings and precautions:

• Heart conditions: anagrelide can increase heart rate and prolong the QT interval, so it is used cautiously in people with heart failure, prior heart attack, valve disease, arrhythmias, or long QT; an ECG before and sometimes during treatment is recommended.
• Lung disease, bleeding problems, or a history of stomach or intestinal bleeding increase risk and warrant close supervision.
• Liver disease: lower starting doses and frequent monitoring are advised in moderate impairment, and the drug is generally avoided in severe hepatic impairment; kidney disease also requires careful monitoring.
• Pregnancy and breastfeeding: human data are limited and animal studies show potential harm to the fetus, so use during pregnancy is usually reserved for situations where the benefits clearly outweigh the risks; breastfeeding is not recommended during treatment and for one week after the last dose.
• Children: safety and effectiveness are established for children 7 years and older; it is not recommended for younger children.

Overall safety compared with similar drugs: Anagrelide does not have a clearly demonstrated risk of causing secondary blood cancers like some older cytoreductive drugs, but it is more likely to cause heart‑ and lung‑related side effects, so many clinicians avoid it in patients with significant cardiovascular disease.

Side effect reporting and safety updates: If you experience side effects, contact your prescriber; in the United States, side effects can also be reported to the FDA MedWatch program (online or by calling 1‑800‑FDA‑1088), where updated safety information on anagrelide is posted.

Drug and supplement interactions:

• Medicines that increase bleeding risk—such as aspirin, NSAIDs (for example ibuprofen or naproxen), clopidogrel, warfarin, heparin, direct oral anticoagulants, and many antidepressants (for example SSRIs)—can raise the chance of serious bleeding when taken with anagrelide.
• Other phosphodiesterase‑3 (PDE3) inhibitors (such as cilostazol or milrinone) may intensify heart effects and are generally avoided in combination.
• Drugs that prolong the QT interval (certain antiarrhythmics, some antibiotics, antipsychotics, and methadone, among others) increase the risk of dangerous heart rhythm disturbances and are usually not used with anagrelide.
• CYP1A2 inhibitors (such as fluvoxamine or ciprofloxacin) can increase anagrelide levels, whereas CYP1A2 inducers (such as omeprazole or tobacco smoke) can decrease them, so dose adjustments and closer monitoring may be needed.
• Digoxin and warfarin have not shown major pharmacokinetic interactions with anagrelide, but patients taking them still require careful clinical monitoring.

Food, alcohol, and other interactions:

• Anagrelide may be taken with or without food, but your prescriber may ask you to be consistent in how you take it.
• Grapefruit and grapefruit juice can affect some drug‑metabolizing enzymes; avoid major changes in grapefruit intake without first discussing them with your clinician.
• Alcohol can worsen dizziness and may increase bleeding risk, so many clinicians recommend limiting or avoiding alcohol while taking anagrelide.
• Smoking and other tobacco use strain the heart and blood vessels and may alter how the body handles anagrelide; avoiding tobacco is strongly advised.

Medical conditions and monitoring needs:

• Tell your clinician if you have or have had heart disease, heart failure, irregular heartbeat, long QT syndrome, prior stroke, lung disease, kidney or liver problems, or a history of serious bleeding or stomach ulcers.
• Before or soon after starting treatment, most patients have a cardiovascular exam and ECG, and during treatment they need regular blood tests, including platelet counts, complete blood counts, kidney and liver function tests, and sometimes electrolyte levels, along with blood pressure and heart‑rate checks.
• If you develop chest pain, marked shortness of breath, severe palpitations, fainting, or signs of bleeding, seek urgent medical care and inform providers that you are taking anagrelide.

Q: What is anagrelide used for?
A: Anagrelide is used to lower very high platelet counts in people with myeloproliferative neoplasms such as essential thrombocythemia, helping reduce the risk of blood clots and bleeding problems.

Q: How long will I need to take anagrelide?
A: Most people need to take anagrelide long term, sometimes for many years, because it controls platelet counts while you are on it but does not cure the underlying bone marrow disease.

Q: How quickly will my platelet count improve after starting anagrelide?
A: Platelet counts often begin to fall within 1–2 weeks, but it may take about 1–3 months of careful dose adjustment to reach and stabilize at your target level.

Q: Can I take anagrelide with aspirin or other blood thinners?
A: Some patients are prescribed low‑dose aspirin or other blood thinners along with anagrelide, but the combination increases bleeding risk, so this should only be done under close supervision and never started or stopped without your prescriber’s guidance.

Q: What tests will I need while taking anagrelide?
A: You will need frequent blood counts at the beginning and then periodically, and your clinician may also monitor your heart with an ECG, check your blood pressure and pulse, and order periodic kidney and liver blood tests.

Q: Is anagrelide safe during pregnancy or breastfeeding?
A: Because safety in pregnancy and breastfeeding is uncertain and there is potential risk to the baby, anagrelide is generally avoided unless clearly needed, and breastfeeding is not recommended during treatment and for one week after the last dose.

Storage: Keep anagrelide capsules at room temperature (68°F–77°F) in the original, tightly closed, light‑resistant bottle, away from moisture, heat, and direct light, and out of reach of children and pets.

Disposal: When the medicine is expired or no longer needed, use a pharmacy or community drug take‑back program if possible, or follow your pharmacist’s or local waste authority’s instructions; do not flush capsules down the toilet unless specifically told it is acceptable.